1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Preprint2025

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial

Christian U. Blank, Lotte Hoeijmakers, Petros Dimitriadis, S C M A Wijnen, Irene L. M. Reijers, Marta López‐Yurda, Alexander M. Menzies, Annegien Broeks, Sten Cornelissen, Alex Torres Acosta, Anja van der Wal, Robyn P.M. Saw, Judith M. Versluis, Winan J. van Houdt, Michel W.J.M. Wouters, Jurriaan Romano, Elisa A. Rozeman, L. Grijpink-Ongering, Ellen Kapiteijn, Astrid van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, Jos A. van der Hage, Dirk J. Grünhagen, Arjen J. Witkamp, Judith Lijnsvelt, W. Martin C. Klop, Charlotte L. Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E. Pennington, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Maria Gonzalez, Andrew Spillane, John B.A.G. Haanen, Robert V. Rawson, Richard A Scolyer, Bart A. van de Wiel, Alexander C.J. van Akkooi, Georgina V. Long

Article2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen,

Article2024

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long

Article2022

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C.J. van Akkooi, Judith M. Versluis, N.M.J. Van Den Heuvel, Robyn P.M. Saw, Thomas E. Pennington, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Elisa A. Rozeman, W. Martin C. Klop, Winan J. van Houdt, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Michel W.J.M. Wouters, Arjen J. Witkamp, Charlotte L. Zuur, Judith Lijnsvelt, A. Torres Acosta,

Article2022

6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Reijers, P. Dimitriadis, J.J. Traets, R. Saw, J.M. Versluis, T. Pennington, E. Kapiteijn, Astrid A.M. van der Veldt, K. Suijkerbuijk, G. Hospers, W. Van Houdt, A. Broeks, S. Cornelissen, A. Spillane, Richard A Scolyer, B. van de Wiel, A.M. Menzies, Alexander C.J. van Akkooi, G.V. Long, C U Blank

Discussion(0)

Related publications